ALMS

MKT CAP:$3B

Alumis Inc

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$18.99+$10.03 (+112.06%)

Jun 8, 2026

52W High $29.9852W Low $2.80

Company Details

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of pl...

CEO

—

IPO Date

Jun 28, 2024

Website

www.alumis.com

Key Metrics TTM

Revenue

$8M

-58.9% YoY

Net Income

-$237M

EPS (Diluted)

Free Cash Flow

-$377M

Revenue / Share

$0.07

Gross Margin

89.6%

Operating Margin

-5364.0%

Net Margin

-2825.7%

FCF Margin

-4487.4%

P/S

308.5x

P/E

Earnings Reports

Q2 2026

Aug 12, 2026

PENDING

Q1 2026

May 14, 2026

$2M-90.0%

FY 2025

Mar 19, 2026

$24M

Q4 2025

Mar 19, 2026

$2M-36.5%

Q3 2025

Nov 13, 2025

$2M

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee